DPP4 and metabolic dysfunction-associated steatotic liver disease: Evogliptin is an effective and safe DPP4 inhibitor approved for treating type 2 diabetes mellitus (T2DM) [24], Although a recent study showed that evogliptin reduces the hepatic fatty burden in patients with T2DM and NAFLD [25], studies on the direct effect of evogliptin on liver inflammation and fibrosis are limited.